• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在存在终末事件的情况下使用标记过程进行非参数效益-风险评估。

Nonparametric Benefit-Risk Assessment Using Marker Process in the Presence of a Terminal Event.

作者信息

Sun Yifei, Huang Chiung-Yu, Wang Mei-Cheng

机构信息

Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD.

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.

出版信息

J Am Stat Assoc. 2017;112(518):826-836. doi: 10.1080/01621459.2016.1180988. Epub 2017 Apr 12.

DOI:10.1080/01621459.2016.1180988
PMID:29731529
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5935274/
Abstract

Benefit-risk assessment is a crucial step in medical decision process. In many biomedical studies, both longitudinal marker measurements and time to a terminal event serve as important endpoints for benefit-risk assessment. The effect of an intervention or a treatment on the longitudinal marker process, however, can be in conflict with its effect on the time to the terminal event. Thus, questions arise on how to evaluate treatment effects based on the two endpoints, for the purpose of deciding on which treatment is most likely to benefit the patients. In this article, we present a unified framework for benefit-risk assessment using the observed longitudinal markers and time to event data. We propose a cumulative weighted marker process to synthesize information from the two endpoints, and use its mean function at a prespecified time point as a benefit-risk summary measure. We consider nonparametric estimation of the summary measure under two scenarios: (i) the longitudinal marker is measured intermittently during the study period, and (ii) the value of the longitudinal marker is observed throughout the entire follow-up period. The large-sample properties of the estimators are derived and compared. Simulation studies and data examples exhibit that the proposed methods are easy to implement and reliable for practical use. Supplemental materials for this article are available online.

摘要

效益风险评估是医学决策过程中的关键一步。在许多生物医学研究中,纵向标志物测量和至终点事件的时间均作为效益风险评估的重要终点。然而,一种干预或治疗对纵向标志物过程的影响可能与其对至终点事件时间的影响相冲突。因此,就如何基于这两个终点评估治疗效果以确定哪种治疗最有可能使患者受益的问题便应运而生。在本文中,我们提出了一个使用观察到的纵向标志物和事件时间数据进行效益风险评估的统一框架。我们提出一个累积加权标志物过程来整合来自这两个终点的信息,并将其在预定时间点的均值函数用作效益风险汇总指标。我们考虑在两种情形下对汇总指标进行非参数估计:(i)在研究期间间歇性地测量纵向标志物;(ii)在整个随访期内观察纵向标志物的值。推导并比较了估计量的大样本性质。模拟研究和数据实例表明,所提出的方法易于实施且在实际应用中可靠。本文的补充材料可在线获取。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9864/5935274/f038da0246c9/nihms931499f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9864/5935274/80afb1fc29be/nihms931499f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9864/5935274/f038da0246c9/nihms931499f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9864/5935274/80afb1fc29be/nihms931499f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9864/5935274/f038da0246c9/nihms931499f2.jpg

相似文献

1
Nonparametric Benefit-Risk Assessment Using Marker Process in the Presence of a Terminal Event.在存在终末事件的情况下使用标记过程进行非参数效益-风险评估。
J Am Stat Assoc. 2017;112(518):826-836. doi: 10.1080/01621459.2016.1180988. Epub 2017 Apr 12.
2
Evaluating Utility Measurement from Recurrent Marker Processes in the Presence of Competing Terminal Events.在存在竞争性终末事件的情况下评估复发标记过程的效用测量。
J Am Stat Assoc. 2017;112(518):745-756. doi: 10.1080/01621459.2016.1166113. Epub 2017 Apr 12.
3
Evaluation of longitudinal surrogate markers.纵向替代标志物的评估。
Biometrics. 2021 Jun;77(2):477-489. doi: 10.1111/biom.13310. Epub 2020 Jun 22.
4
Nonparametric estimation for cumulative duration of adverse events.不良事件累积持续时间的非参数估计
Biom J. 2012 Jan;54(1):61-74. doi: 10.1002/bimj.201000256. Epub 2011 Dec 14.
5
Joint modeling of repeated multivariate cognitive measures and competing risks of dementia and death: a latent process and latent class approach.重复多变量认知测量与痴呆和死亡竞争风险的联合建模:一种潜在过程和潜在类别方法。
Stat Med. 2016 Feb 10;35(3):382-98. doi: 10.1002/sim.6731. Epub 2015 Sep 16.
6
Using a surrogate marker for early testing of a treatment effect.使用替代标志物进行治疗效果的早期检测。
Biometrics. 2019 Dec;75(4):1253-1263. doi: 10.1111/biom.13067. Epub 2019 Apr 22.
7
Designing phase II studies in cancer with time-to-event endpoints.设计以事件发生时间为终点的癌症II期研究。
Clin Trials. 2008;5(3):209-21. doi: 10.1177/1740774508091748.
8
The partly Aalen's model for recurrent event data with a dependent terminal event.具有相依终末事件的复发事件数据的部分阿伦模型。
Stat Med. 2016 Jan 30;35(2):268-81. doi: 10.1002/sim.6625. Epub 2015 Aug 11.
9
Analyzing semi-competing risks data with missing cause of informative terminal event.分析具有信息性终末事件缺失原因的半竞争风险数据。
Stat Med. 2017 Feb 28;36(5):738-753. doi: 10.1002/sim.7161. Epub 2016 Nov 3.
10
On longitudinal prediction with time-to-event outcome: Comparison of modeling options.关于具有事件发生时间结局的纵向预测:建模选项的比较。
Biometrics. 2017 Mar;73(1):83-93. doi: 10.1111/biom.12562. Epub 2016 Jul 20.

本文引用的文献

1
Statistical inference methods for recurrent event processes with shape and size parameters.具有形状和大小参数的复发事件过程的统计推断方法。
Biometrika. 2014 Sep 1;101(3):553-566. doi: 10.1093/biomet/asu016.
2
The standard error of an estimate of expectation of life, with special reference to expectation of tumourless life in experiments with mice.寿命预期估计值的标准误差,特别涉及小鼠实验中无瘤生存期的预期。
J Hyg (Lond). 1949 Jun;47(2):188. doi: 10.1017/s0022172400014443.
3
Joint modelling of longitudinal measurements and event time data.
纵向测量数据与事件时间数据的联合建模
Biostatistics. 2000 Dec;1(4):465-80. doi: 10.1093/biostatistics/1.4.465.
4
Allowing for differential timing in cost analyses: discounting and annualization.在成本分析中考虑不同的时间安排:贴现和年度化。
Health Policy Plan. 2002 Mar;17(1):112-8. doi: 10.1093/heapol/17.1.112.
5
Non-parametric methods for recurrent event data with informative and non-informative censorings.用于具有信息性和非信息性删失的复发事件数据的非参数方法。
Stat Med. 2002 Feb 15;21(3):445-56. doi: 10.1002/sim.1029.
6
Discounting for health effects in cost-benefit and cost-effectiveness analysis.成本效益分析和成本效果分析中健康效应的贴现
Health Econ. 2001 Oct;10(7):587-99. doi: 10.1002/hec.618.
7
A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.一项关于β受体阻滞剂布新洛尔用于晚期慢性心力衰竭患者的试验。
N Engl J Med. 2001 May 31;344(22):1659-67. doi: 10.1056/NEJM200105313442202.
8
Efficient estimation of the distribution of quality-adjusted survival time.质量调整生存时间分布的有效估计。
Biometrics. 1999 Dec;55(4):1101-7. doi: 10.1111/j.0006-341x.1999.01101.x.
9
Variance and sample size calculations in quality-of-life--adjusted survival analysis (Q-TWiST).
Biometrics. 2000 Mar;56(1):173-82. doi: 10.1111/j.0006-341x.2000.00173.x.
10
Expressing estimators of expected quality adjusted survival as functions of Nelson-Aalen estimators.将预期质量调整生存的估计量表示为Nelson-Aalen估计量的函数。
Lifetime Data Anal. 1999 Sep;5(3):199-212. doi: 10.1023/a:1009657629713.